Effect of Zizyphus jujuba extract on the inhibition of adipogenesis in 3T3-L1 preadipocytes.
Kubota H., Morii R., Kojima-Yuasa A., Huang X., Yano Y., Matsui-Yuasa I.
Animal Study, published in Am J Chin Med (2009) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Am J Chin Med (2009)
- Country
- Singapore
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 19606518
- DOI
- 10.1142/S0192415X09007089
Abstract (original English)
Obesity, the leading metabolic disease in the world, is a serious health problem in industrialized countries. The Zizyphus jujuba fruit has been used as traditional Chinese medicinal herb and considered to affect various physiological functions in the body for thousands of years. We investigated the anti-obesity effect of Z. jujuba on adipocyte differentiation of 3T3-L1 preadipocytes and found that treatment with an extract of Z. jujuba suppressed lipid accumulation and glycerol-3-phosphate dehydrogenase (GPDH) activity without affecting cell viability. Further fractionation of the initial Z .jujuba extract with organic solvent revealed that the chloroform fraction (CHCl(3)-F) elicited the most inhibitory effect, which involved significant attenuation of the expression of key adipogenic transcription factors, including peroxisome proliferator-activated receptor (PPAR)gamma and CCAAT enhancer binding proteins (C/EBPs) at the protein level. These results suggest that CHCl(3)-F may block adipogenesis, at least in part, by decreasing the expression of PPARgamma, C/EBPalpha and beta.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.